Increase in major osteoporotic fractures after therapy with immune checkpoint inhibitors
Patients who receive ICI are at increased risk of MOF after receiving therapy. Given the plausible biological pathway, osteoporosis and osteoporotic fractures may represent a novel irAE of ICI therapy.
Authors
- Noha Abdel‐Wahab (ORCID: https://orcid.org/0000-0002-7621-9266)
- Hui Zhao (ORCID: https://orcid.org/0000-0003-4742-1139)
- Carrie Ye (ORCID: https://orcid.org/0000-0002-9858-5398)
- Maria Eugenia Suarez-Almazor (ORCID: https://orcid.org/0000-0001-5381-5797)
- William D. Leslie (ORCID: https://orcid.org/0000-0002-1056-1691)
- Bo Zhao (ORCID: https://orcid.org/0000-0002-2466-1343)
- Juan Ignacio Ruiz (ORCID: https://orcid.org/0000-0002-0885-134X)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- University of Alberta (CA)
- Assiut University Hospitals (EG)
- University of Manitoba (CA)
Publication Details
- Journal
- BMJ Oncology
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1136/bmjonc-2024-000398
- Citations
- 10
- Primary Topic
- Bone health and treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.83
Funders
- Duncan Family Institute for Cancer Prevention and Risk Assessment
- University of Texas MD Anderson Cancer Center
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases